Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 27, 2026 08:01 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

SAN CARLOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
April 21, 2026 10:26 ET | Source: https://immatics.com/

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage...
April 17, 2026 15:00 ET | Source: https://immatics.com/

PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma

Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TCR T-cell therapy engineered with a PRAME-directed TCR...
April 14, 2026 07:00 ET | Source: EvolveImmune Therapeutics

EvolveImmune Therapeutics to Present Update on Lead Asset EVOLVE104 and New Data for EVOLVE T Cell Engager Platform at 2026 AACR Annual Meeting

Poster Presentation to Spotlight Ongoing Phase 1 Clinical Trial of EVOLVE104 Oral and Poster Presentations to Highlight Preclinical Data Demonstrating Ability of EVOLVE Platform to Drive Enhanced T...
March 05, 2026 07:00 ET | Source: https://immatics.com/

Immatics Announces Full Year 2025 Financial Results and Business Update

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug...
February 24, 2026 07:00 ET | Source: Iovance Biotherapeutics, Inc.

Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas

50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 ...
December 16, 2025 07:00 ET | Source: EvolveImmune

EvolveImmune Therapeutics Announces Initiation of Dosing in a Phase 1 Trial of EVOLVE104 in Patients with Solid Tumors

EVOLVE104, a First-in-Class CD2 Costimulatory Trispecific T Cell Engager, is First Molecule from EVOLVE Platform to Enter the Clinic Trial Initiation Marks EvolveImmune’s Transition to Clinical-Stage...
December 11, 2025 07:00 ET | Source: https://immatics.com/

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable tolerability across all dose levelsEncouraging early clinical anti-tumor...
December 05, 2025 06:00 ET | Source: https://immatics.com/

Immatics Announces $125 Million Underwritten Offering

Houston, Texas and Tuebingen, Germany, December 05, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company and the global leader in precision...
November 17, 2025 07:00 ET | Source: https://immatics.com/

Immatics Announces Third Quarter 2025 Financial Results and Business Update

Anzu-cel (anzutresgene autoleucel, IMA203) PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will...